van Wijnen, Alexandra
Petrov, Franca
Maiworm, Michelle
Frisch, Stefan
Foerch, Christian
Hattingen, Elke
Steinmetz, Helmuth
Klein, Johannes C.
Deichmann, Ralf
Wagner, Marlies
Gracien, René-Maxime http://orcid.org/0000-0003-1065-940X
Funding for this research was provided by:
State of Hesse with a LOEWE-Grant to the CePTER-Consortium
Clinician Scientists program at Goethe university
Article History
Received: 25 April 2019
Revised: 8 August 2019
Accepted: 4 September 2019
First Online: 10 October 2019
Compliance with ethical standards
:
: The scientific guarantor of this publication is René-Maxime Gracien.
: The authors report no conflicts of interest relevant to this study. Dr H Steinmetz has received speaker’s honoraria from Bayer, Sanofi, and Boehringer Ingelheim.Dr JC Klein received speaker honoraria and travel reimbursement from Medtronic, AstraZeneca, Abbott Laboratories, and AbbVie.Dr Elke Hattingen has received speaker’s honoraria from BRACCO.Dr R Deichmann received compensation as a Consultant for MR scanner procurement by the Wellcome Trust Centre for Neuroimaging, UCL, London, UK.
: No complex statistical methods were necessary for this paper.
: Written informed consent was obtained from all subjects in this study.
: Institutional ethics committee approval was obtained.
: Eleven patients overlap with a previous neuropsychological study: Yalachkov Y, Soydaş D, Bergmann J, Frisch S, Behrens M, Foerch C et al (2019) Determinants of quality of life in relapsing-remitting and progressive multiple sclerosis. Multiple sclerosis and related disorders 30:33–7
: • prospective• cross-sectional study• performed at one institution